Lilly Announces Acquisition of Centessa Pharmaceuticals to Expand Pipeline in Sleep-Wake Disorder Treatments Eli Lilly and Company and Centessa Pharmaceuticals plc have announced a definitive agreement under which Lilly will acquire Centessa in a transaction that underscores the growing strategic…
Omeros Corporation Releases Fourth Quarter and Full-Year 2025 Financial Results Omeros Corporation has reported a transformative set of financial and operational results for the fourth quarter and full year ended December 31, 2025, marking a pivotal period in the company’s…
Tanner Pharma Group and Biodexa Introduce Global Early Access Initiative for Patients with Familial Adenomatous Polyposis (FAP) Tanner Pharma Group, a globally recognized provider of specialty medicine access solutions, has entered into a strategic partnership with Biodexa Pharmaceuticals PLC, a…
WuXi Biologics Earns CDMO Leadership Awards for the Ninth Straight Year WuXi Biologics has once again reinforced its leadership position in the global biologics outsourcing sector, announcing that it has been named “Biologics CDMO of the Year” in the Large…
FDA Approves Higher-Dose SPINRAZA® (Nusinersen) Regimen for Spinal Muscular Atrophy Biogen Inc. has announced a significant regulatory milestone with the approval of a new high-dose regimen of SPINRAZA (nusinersen) by the U.S. Food and Drug Administration for the treatment of…
Alnylam Highlights New Cardiovascular Data at ACC.26, Reinforcing Potential of RNAi Therapies in ATTR-CM and Hypertension Alnylam Pharmaceuticals has unveiled a comprehensive set of new clinical and real-world findings from its cardiovascular portfolio at the American College of Cardiology Annual…
PepGen Reports Encouraging Phase 2 Data for PGN-EDODM1 in Myotonic Dystrophy Type 1, Advances Higher-Dose Cohort in FREEDOM2 Trial PepGen Inc., a clinical-stage biotechnology company focused on advancing next-generation oligonucleotide therapeutics, has announced new clinical data from the 5 mg/kg…
Roche Launches cobas MPX-E, a 4-in-1 Donor Screening Assay to Strengthen Global Blood Supply Safety Roche has announced the availability of its cobas® MPX-E assay, a next-generation qualitative in vitro diagnostic test designed to detect and differentiate multiple high-risk viral…
Incyte Reports Positive 54-Week Late-Breaking Povorcitinib Data in Hidradenitis Suppurativa at AAD 2026 Incyte has reported new long-term findings from its pivotal Phase 3 STOP-HS clinical development program, highlighting the sustained safety and efficacy of povorcitinib (INCB54707), an investigational oral,…
Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescents with Symptomatic oHCM Bristol Myers Squibb has announced compelling results from its pivotal Phase 3 SCOUT-HCM clinical trial, highlighting the potential of Camzyos (mavacamten) as a transformative…
Novartis Agrees to Acquire Excellergy, Inc. to Strengthen Allergy Leadership with Next-Generation Anti-IgE Innovation Novartis has announced a strategic agreement to acquire Excellergy, a privately held biotechnology company focused on the development of next-generation therapies targeting immunoglobulin E (IgE)-driven diseases.…
Ono Pharma Files for Approval of Ripretinib (DCC-2618) to Treat Advanced Gastrointestinal Stromal Tumors in Japan Ono Pharmaceutical Co., Ltd. has announced the submission of a regulatory application in Japan seeking manufacturing and marketing approval for ripretinib (DCC-2618), an investigational…